Journal
CURRENT TREATMENT OPTIONS IN NEUROLOGY
Volume 17, Issue 1, Pages -Publisher
CURRENT MEDICINE GROUP
DOI: 10.1007/s11940-014-0326-1
Keywords
Pediatric migraine; Primary headache; Treatment; NSAIDs; Triptans; Dopamine antagonists; DHE; Nutraceuticals; Chronic migraine
Categories
Funding
- Labry Biologics
- GlaxoSmithKline
- Merck
Ask authors/readers for more resources
The diagnosis of migraine in the pediatric population is increasing as providers are becoming more familiar with recognizing the condition. Over-the-counter and migraine-specific treatment, once considered off-label, have proven to be effective, especially if given at the early onset of head pain. Mild to severe cases of migraine should be treated with nonsteroidal anti-inflammatory drugs (NSAIDs), with triptans used alone or in combination in moderate to severe headaches unresponsive to over-the-counter therapy. Rescue medication including dihydroergotamine (DHE), a potent vasoconstrictor should be used for intractable migraines and is preferred in the hospital setting. Anti-emetics that have anti-dopaminergic properties can be helpful in patients with associated symptoms of nausea and vomiting along with headache, especially when used in combination therapy. Preventative treatment should be initiated early in patients with frequent headaches to improve headache outcomes and quality of life. Patients and families should be educated on non-pharmacologic management, such as lifestyle modification and avoidance of triggers, that can prevent progression and worsening of migraine.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available